Encorafenib/Binimetinib/Nivolumab Improves PFS in BRAF V600+ Melanoma with Symptomatic Brain Metastases

Publication date: Jun 28, 2025

No patients in either arm received neoadjuvant therapy alone; 6. 3% of patients in the triplet arm had adjuvant therapy alone compared with 13% of patients in the doublet arm. Thirteen percent of patients in the triplet arm had progressive disease vs 79% of patients in the control arm. One patient in the triplet arm (6. 3%) received both neoadjuvant and adjuvant therapy. Most patients in the triplet (75%) and doublet (53%) arms had 1 or 2 brain metastases. Elevated lactate dehydrogenase levels were reported in 44% of patients in the triplet arm and 73% of patients in the control arm. Corticosteroid use was reported in 38% and 47% of patients, respectively. Thirty-one percent of patients in the triplet arm received prior brain surgery, and 13% had prior brain-directed radiotherapy. A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013). Patients were allowed to have leptomeningeal disease, but extracranial disease was not allowedPatients needed to harbor a BRAF V600 mutation and be treatment naive in the metastatic setting.

Semantics